Application of Platelet-rich Plasma (PRP) in Reproductive Medicine

Launched by THE FOURTH AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE · Oct 14, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of platelet-rich plasma (PRP) as a potential treatment for various fertility issues in women. These issues include conditions like premature ovarian insufficiency (when the ovaries do not produce enough hormones), poor ovarian response during fertility treatments, intrauterine adhesions (scar tissue in the uterus), repeated implantation failures after embryo transfers, and having a thin endometrium (the lining of the uterus). Previous studies suggest that PRP might help improve these conditions, and this trial aims to understand how effective it can be.

To participate in the trial, women between the ages of 18 and 40 with specific fertility challenges can apply. For example, if someone has experienced missed periods for over four months, has a low number of eggs, or has had trouble getting pregnant after transferring quality embryos, they may qualify. Those interested can expect to receive treatment with PRP and will be monitored throughout the process. However, certain medical conditions, such as severe liver issues, bleeding disorders, or serious mental health problems, may exclude individuals from participating. If you're considering joining this trial, it could be a promising opportunity to explore new options for improving fertility.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Premature ovarian insufficiency: ① Women aged \>18 and \<40 years old; ② Oligomenorrhea or amenorrhea for more than 4 months (excluding pregnancy); ③ Basal follicle stimulating hormone (FSH) \>25IU/L (interval \>4 weeks) at least 2 times, or total antral follicles (AFC) \<5, or anti-Mullerian hormone (AMH) \<1.1ng/mL.
• • Poor ovarian response: ① Advanced age (≥40 years) or other risk factors for poor ovarian response; ② Poor ovarian response in previous IVF cycle, with ≤3 oocytes retrieved using conventional protocols; ③ Decreased ovarian reserve (antral follicle count \<5\~7 or anti-Müllerian hormone \<0.5\~1.1 ug/L). Meeting any 2 of the above 3 criteria is sufficient.
• • Intrauterine adhesion: ① Diagnosed by hysteroscopy and scored ≥5 points according to the American Fertility Society criteria (1988); ② With symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ Adult women with the desire to conceive.
• • Thin endometium: ①Endometrial thickness \<7mm on ovulation day or on the day of human chorionic gonadotropin (HCG) injection, or \<7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive.
• • Repeated implantation failure: Women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. High-quality embryos include: Day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \<10% fragmentation) and blastocysts (≥3BB).
• Exclusion Criteria:
• • Alanine aminotransferase \> 3 times the normal upper limit or estimated glomerular filtration rate (EGFR) \< 90 ml/min;
• • Suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs;
• • Suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors;
• • Suffering from diabetes with poor blood sugar control or other systemic diseases;
• • Drug abuse, alcoholism or drug addiction;
• • Participated in other interventional clinical studies within half a year;
• • Poor compliance;
• • Other circumstances that are not suitable for participating in the study.